title: Summaries for patients: Dapagliflozin treatment in patients with inadequately controlled type 2 diabetes despite the use of insulin.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds; D001786:Blood Glucose / Q000378:metabolism; D002648:Child; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005831:Genital Diseases, Female / Q000139:chemically induced; D005832:Genital Diseases, Male / Q000139:chemically induced; D005960:Glucosides / Q000009:adverse effects / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D051247:Sodium-Glucose Transport Proteins / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome; D015431:Weight Loss; D055815:Young Adult
chemical_list: D001559:Benzhydryl Compounds; D001786:Blood Glucose; D005960:Glucosides; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D051247:Sodium-Glucose Transport Proteins; C529054:dapagliflozin